ZeOmega Completes 2015 Review of its Evidence-based Clinical Content for Patient Centered Care Management

PLANO, Texas – April 21, 2015 – ZeOmega Inc., a market leader in population health and care coordination solutions, today released its annual clinical content update which enables its clients to access the latest best practices in evidence-based medicine and care management. The interactive clinical protocols are built on industry standards such as NCQA HEDIS and are fully integrated with Jiva, ZeOmega’s end-to-end population health platform. Jiva enables event-driven care coordination workflows that empower care teams to collaborate on a patient’s care needs. The interactive clinical protocols empower healthcare organizations to automatically generate care plans that are personalized to the patient’s specific needs and trigger care coordination activities across multi-disciplinary care teams.

The clinical assessments are based on a holistic approach that not only covers more than 24 diseases and conditions but also considers the seven domains of a patient’s health – intellectual, emotional, physical, spiritual, social/cultural, occupational and environmental. The clinical content is also tailored to address the unique needs of patients of all ages, and their caregivers, and covers the psychosocial context of the patient in making recommendations on care coordination needs.

“It is now widely acknowledged by payers and providers alike that to achieve population health goals – in other words improving the overall health and wellbeing of the individuals they serve – healthcare organizations need to look at every individual holistically. With Jiva and its rich content, healthcare organizations can coordinate care for the patient holistically as opposed to managing them for a specific condition thereby positioning them to achieve Triple Aim goals of improved patient experience, optimized health outcomes and lower costs,” said ZeOmega Chief Medical Officer Dr. Christopher Mathews. “By having an intuitive, predictive system that uses actionable intelligence, ZeOmega’s integrated protocols deliver event-driven workflows that support evidence-based clinical decisions and recommend the most appropriate action for the patient at the right time in the right setting. This streamlines interactions across the entire care management team, allowing different care providers to collaborate meaningfully on the patient’s care.”

These integrated assessments are also being configured to work on various mobility applications so they can be used not only within the four walls of a healthcare organization but also by multi-disciplinary care teams working in various care settings in the community.

ZeOmega updates its content annually so that Jiva customers always have the latest information; likewise, their patients benefit from Jiva’s evidence-based medicine and care management best practices.

 

About ZeOmega

ZeOmega’s powerful population health platform delivers high-value, strategic solutions enabling payers and care-delivery organizations to improve individual health and provider performance. With deep domain expertise and a comprehensive understanding of complex population health challenges, ZeOmega serves as a “true-north” partner for clients—offering flexible deployment and delivery models that leverage an innovative platform designed to integrate workflow, analytics, content and communication capabilities. By consistently meeting customer expectations and project benchmarks, ZeOmega has earned a sterling reputation in the industry for responsiveness and reliability. For more information, visit www.zeomega.com or call 214-618-9880. Follow ZeOmega on Twitter, LinkedIn or Facebook.

 

# # #

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.